INS and metabolic dysfunction-associated steatotic liver disease: On the other hand, tissue-restricted FXR agonists can improve insulin sensitivity and reduce hepatic steatosis in HFD mice and non-diabetic NAFLD patients (Carino et al., 2017; Traussnigg et al., 2021).